BTC Capital Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,846 shares of the company’s stock after purchasing an additional 155 shares during the period. Johnson & Johnson makes up 1.6% of BTC Capital Management Inc.’s investment portfolio, making the stock its 8th biggest holding. BTC Capital Management Inc.’s holdings in Johnson & Johnson were worth $13,484,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of JNJ. Patron Partners LLC lifted its position in Johnson & Johnson by 12.7% during the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after acquiring an additional 747 shares during the last quarter. Palisade Capital Management LLC NJ lifted its position in Johnson & Johnson by 0.3% during the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock worth $16,507,000 after acquiring an additional 250 shares during the last quarter. Lmcg Investments LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $12,462,000. Capital Wealth Planning LLC lifted its position in Johnson & Johnson by 14.0% during the 1st quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock worth $162,445,000 after acquiring an additional 112,890 shares during the last quarter. Finally, Tandem Investment Advisors Inc. raised its position in shares of Johnson & Johnson by 4.8% during the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after buying an additional 15,003 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors.
Insider Transactions at Johnson & Johnson
In other news, insider William Hait sold 15,000 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $13,764,485.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold a total of 118,795 shares of company stock worth $20,230,174 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the business posted $2.60 earnings per share. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.
Johnson & Johnson announced that its board has authorized a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s payout ratio is 62.95%.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on JNJ shares. Citigroup cut their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Finally, SVB Leerink lowered their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $184.25.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.